We examined the impact of single and combination therapy with GB1211 (10 mg/kg, twice daily orally) and anti-PD-L1 treatment (200 mg i.p. twice weekly for 4 administration) in a syngeneic mouse LLC1 lung adenocarcinoma model that has been shown to be resistant to anti-PD-L1 therapeutic antibodies (20–22). This evidence concerns the gene CD274 and lung adenocarcinoma.